Positive data for Zafgen's obesity candidate give indication a boost
This article was originally published in Scrip
Executive Summary
Zafgen, a biopharmaceutical firm based in Cambridge, Massachusetts, US, says its lead compound, ZGN-433, for severely obese patients, has met both its primary and secondary endpoints in a Phase Ib trial. The level of weight loss observed was close to the levels that are only exceeded by surgical intervention, according to the company.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.